Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988951 | 0.95 | KDM4E (0.35) | KDM4EATML3MBTL1GSRPDE1B | |
| SCHEMBL23031027 | 0.94 | KDM4E (0.32) | KDM4EATML3MBTL1 | |
| SCHEMBL24245807 | 0.90 | L3MBTL1 (0.41) | KDM4EATML3MBTL1GSRMEN1 | |
| SCHEMBL23031022 | 0.89 | KDM4E (0.32) | KDM4EATML3MBTL1 | |
| SCHEMBL24245686 | 0.88 | KDM4E (0.36) | KDM4EATML3MBTL1GSRMEN1 | |
| SCHEMBL22989047 | 0.87 | L3MBTL1 (0.35) | KDM4EATML3MBTL1ALDH1A1RXFP1 | |
| SCHEMBL21366854 | 0.87 | L3MBTL1 (0.35) | KDM4EATML3MBTL1ALDH1A1RXFP1 | |
| SCHEMBL24245536 | 0.87 | KDM4E (0.35) | KDM4EATML3MBTL1ALDH1A1RXFP1 | |
| SCHEMBL18623571 | 0.87 | KDM4E (0.40) | KDM4EATML3MBTL1GSRMEN1 | |
| SCHEMBL24839414 | 0.86 | KDM4E (0.35) | KDM4EATML3MBTL1ALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021029757-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2021-02-18 | — | — | WO | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | KDM4E 568/4885ATM 1893/4885L3MBTL1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.